{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:47:38Z","timestamp":1792788458025,"version":"4.5.0"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"WWTF","award":["LS 19-018"],"award-info":[{"award-number":["LS 19-018"]}],"id":[{"id":"https:\/\/ror.org\/01f9mc681","id-type":"ROR","asserted-by":"crossref"}]},{"name":"WWTF","award":["LS 20-065"],"award-info":[{"award-number":["LS 20-065"]}],"id":[{"id":"https:\/\/ror.org\/01f9mc681","id-type":"ROR","asserted-by":"crossref"}]},{"name":"FWF","award":["T 1145-B"],"award-info":[{"award-number":["T 1145-B"]}]},{"name":"BFWF","award":["BG 02\/2025"],"award-info":[{"award-number":["BG 02\/2025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol Exp"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Theranostics integrates diagnostic imaging and therapy within a single platform, enabling image-guided treatment delivery, real-time monitoring, and therapeutic optimization. The choice of imaging modality fundamentally shapes the design, functionality, and clinical maturity of theranostic systems. This review examines the theranostic concept through the lens of major imaging modalities employed in clinical and preclinical practice, including positron emission tomography (PET), single-photon emission computed tomography (SPECT), ultrasound (US), optical imaging (OI), magnetic resonance imaging (MRI), and computed tomography (CT). Beyond modality-specific approaches, the review highlights emerging multimodal theranostic strategies that integrate complementary imaging technologies to overcome individual limitations, enhance biological specificity, and improve treatment guidance. For each modality, we discuss the structural components of theranostic agents, their mechanisms of action, and the balance between diagnostic sensitivity and therapeutic efficacy. The review also highlights current and emerging clinical applications across major disease areas, while critically addressing limitations, such as spatial resolution, depth penetration, toxicity, and translational barriers. Overall, this article underscores that theranostics are expanding from modality-defined implementation toward integrated, multimodal strategies that are likely to shape the next generation of personalized and precision imaging-guided therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:bold>\n                        <jats:italic>Relevance statement<\/jats:italic>\n                      <\/jats:bold>\n                    <\/jats:title>\n                    <jats:p>Imaging modality-driven theranostic design enables more precise, adaptive, and personalized image-guided therapies by aligning diagnostic sensitivity with therapeutic mechanisms, thereby improving treatment selection, response monitoring, and translational integration across clinical disciplines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Theranostics is determined by the underlying imaging modality rather than by a unified theranostic framework.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Imaging modality dictates integration strategy.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Nuclear medicine theranostics are clinically established, while MRI-, CT-, ultrasound-, and optical-based theranostics remain largely translational or function primarily as image-guided therapies.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Multimodal theranostics address modality-specific limitations.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Future progress depends on imaging-driven design and standardization.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41747-026-00823-x","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:37:21Z","timestamp":1791448641000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond radiotheranostics: how imaging modality defines theranostics"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0312-6461","authenticated-orcid":false,"given":"Irena","family":"Pashkunova-Martic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas H.","family":"Helbich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"823_CR1","unstructured":"European Medicines Agency (n.d.) Lutathera. Amsterdam: European Medicines Agency; accessed on 2026 Feb 2. Available via http:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lutathera"},{"key":"823_CR2","unstructured":"European Medicines Agency. Pluvicto. Amsterdam: European Medicines Agency; accessed on 2026 Feb 2. Available via http:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pluvicto"},{"key":"#cr-split#-823_CR3.1","unstructured":"MarketsandMarkets (2024) Theranostics market worth $4.3 billion"},{"key":"#cr-split#-823_CR3.2","unstructured":"accessed on 2026 Feb 2. Available via http:\/\/www.prnewswire.com\/news-releases\/theranostics-market-worth-4-3-billion--marketsandmarkets-302047673.html"},{"key":"823_CR4","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4274\/mirt.galenos.2020.83703","volume":"29","author":"JD Ehrhardt","year":"2020","unstructured":"Ehrhardt JD, G\u00fcle\u00e7 S (2020) A review of the history of radioactive iodine theranostics: the origin of nuclear ontology. Mol Imaging Radionucl Ther 29:88\u201397. https:\/\/doi.org\/10.4274\/mirt.galenos.2020.83703","journal-title":"Mol Imaging Radionucl Ther"},{"key":"823_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1001\/jama.1946.02870190005002","volume":"131","author":"S Hertz","year":"1946","unstructured":"Hertz S, Roberts A (1946) Radioactive iodine in the study of thyroid physiology: VII. The use of radioactive iodine therapy in hyperthyroidism. J Am Med Assoc 131:81\u201386. https:\/\/doi.org\/10.1001\/jama.1946.02870190005002","journal-title":"J Am Med Assoc"},{"key":"823_CR6","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1001\/jama.1946.02870190010003","volume":"131","author":"EM Chapman","year":"1946","unstructured":"Chapman EM, Evans RD (1946) The treatment of hyperthyroidism with radioactive iodine. JAMA 131:86\u201391. https:\/\/doi.org\/10.1001\/jama.1946.02870190010003","journal-title":"JAMA"},{"key":"823_CR7","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","volume":"132","author":"SM Seidlin","year":"1946","unstructured":"Seidlin SM, Marinelli LD, Oshry E (1946) Radioactive iodine therapy: effect on functioning metastases of adenocarcinoma of the thyroid. JAMA 132:838\u2013847. https:\/\/doi.org\/10.1001\/jama.1946.02870490016004","journal-title":"JAMA"},{"key":"823_CR8","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/jlcr.3891","volume":"64","author":"T Ferris","year":"2021","unstructured":"Ferris T, Carroll L, Jenner S, Aboagye EO (2021) Use of radioiodine in nuclear medicine\u2014a brief overview. J Labelled Comp Radiopharm 64:92\u2013108. https:\/\/doi.org\/10.1002\/jlcr.3891","journal-title":"J Labelled Comp Radiopharm"},{"key":"823_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3978\/j.issn.2223-4292.2013.12.06","volume":"3","author":"J-M Id\u00e9e","year":"2013","unstructured":"Id\u00e9e J-M, Louguet S, Ballet S, Corot C (2013) Theranostics and contrast-agents for medical imaging: a pharmaceutical company viewpoint. Quant Imaging Med Surg 3:292\u2013297. https:\/\/doi.org\/10.3978\/j.issn.2223-4292.2013.12.06","journal-title":"Quant Imaging Med Surg"},{"key":"823_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13244-015-0394-0","volume":"6","author":"European Society of Radiology (ESR)","year":"2015","unstructured":"European Society of Radiology (ESR) (2015) Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR). Insights Imaging 6:141\u2013155. https:\/\/doi.org\/10.1007\/s13244-015-0394-0.","journal-title":"Insights Imaging"},{"key":"823_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-bioeng-070909-105249","volume":"12","author":"K Cleary","year":"2010","unstructured":"Cleary K, Peters TM (2010) Image-guided interventions: technology review and clinical applications. Annu Rev Biomed Eng 12:119\u2013142. https:\/\/doi.org\/10.1146\/annurev-bioeng-070909-105249","journal-title":"Annu Rev Biomed Eng"},{"key":"823_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.152346","volume":"778","author":"E Rama","year":"2025","unstructured":"Rama E, May JN, Rix A, Lammers T, Kiessling F (2025) Image-guided strategies to improve drug delivery to tumors beyond using the enhanced permeability and retention (EPR) effect. Biochem Biophys Res Commun 778: 152346. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152346","journal-title":"Biochem Biophys Res Commun"},{"key":"823_CR13","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1967\/s002449912762","volume":"27","author":"R Spyros","year":"2024","unstructured":"Spyros R (2024) Theranostics, Theragnostics, or Iama-gnostics? Hell J Nucl Med 27:253. https:\/\/doi.org\/10.1967\/s002449912762","journal-title":"Hell J Nucl Med"},{"key":"823_CR14","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00259-018-4204-z","volume":"46","author":"S Frangos","year":"2019","unstructured":"Frangos S, Buscombe JR (2019) Why should we be concerned about a \u201cg\u201d? Eur J Nucl Med Mol Imaging 46:519. https:\/\/doi.org\/10.1007\/s00259-018-4204-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"823_CR15","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.1007\/s00330-020-06938-y\/Published","volume":"30","author":"TH Helbich","year":"2020","unstructured":"Helbich TH (2020) A closer look into ECR 2020 on hybrid, molecular, and translational imaging. Eur Radiol 30:5536\u20135538. https:\/\/doi.org\/10.1007\/s00330-020-06938-y\/Published","journal-title":"Eur Radiol"},{"key":"823_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12149-025-02151-3","volume":"40","author":"HMC Vu","year":"2026","unstructured":"Vu HMC, Kayano D, Wakabayashi H, Kuroda R, Kinuya S (2026) Clinical applications and future directions of Iodine-131-Metaiodobenzylguanidine therapy in neuroblastoma: from salvage treatment to frontline integration. Ann Nucl Med 40:248\u2013263. https:\/\/doi.org\/10.1007\/s12149-025-02151-3","journal-title":"Ann Nucl Med"},{"key":"823_CR17","unstructured":"European Medicines Agency (n.d.) Xofigo. Amsterdam: European Medicines Agency; accessed on 2026 Feb 2. Available via http:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xofigo"},{"key":"823_CR18","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.2967\/jnumed.123.266458","volume":"64","author":"S Hoberuck","year":"2023","unstructured":"Hoberuck S, Zophel K, Pomper MG, Rowe SP, Gafita A (2023) One hundred years of the tracer principle. J Nucl Med 64:1998\u20132000. https:\/\/doi.org\/10.2967\/jnumed.123.266458","journal-title":"J Nucl Med"},{"key":"823_CR19","doi-asserted-by":"publisher","first-page":"232","DOI":"10.7150\/THNO.62851","volume":"27","author":"C Miller","year":"2022","unstructured":"Miller C, Rousseau J, Ramogida CF, Celler A, Rahmim A, Uribe CF (2022) Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs. Theranostics 27:232\u2013259. https:\/\/doi.org\/10.7150\/THNO.62851","journal-title":"Theranostics"},{"key":"823_CR20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2967\/jnumed.123.266930","volume":"64","author":"MS Hofman","year":"2023","unstructured":"Hofman MS (2023) The hierarchy of SUVs: from diagnostics to therapeutics and the pathway to effective theranostics. J Nucl Med 64:1845\u20131847. https:\/\/doi.org\/10.2967\/jnumed.123.266930","journal-title":"J Nucl Med"},{"key":"823_CR21","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.7150\/thno.19782","volume":"7","author":"T Li","year":"2017","unstructured":"Li T, Ao ECI, Lambert B, Brans B, Vandenberghe S, Mok GSP (2017) Quantitative imaging for targeted radionuclide therapy dosimetry\u2014Technical review. Theranostics 7:4551\u20134565. https:\/\/doi.org\/10.7150\/thno.19782","journal-title":"Theranostics"},{"key":"823_CR22","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1021\/acscentsci.3c01050","volume":"9","author":"GD Bowden","year":"2023","unstructured":"Bowden GD, Scott PJH, Boros E (2023) Radiochemistry: a hot field with opportunities for cool chemistry. ACS Cent Sci 9:2183\u20132195. https:\/\/doi.org\/10.1021\/acscentsci.3c01050","journal-title":"ACS Cent Sci"},{"key":"823_CR23","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1039\/d5dt02352a","volume":"55","author":"G Ferrari","year":"2026","unstructured":"Ferrari G, Lopez-Martinez I, Saqawa M et al (2026) \u2076\u2078Ga radiolabeling strategies in Pt(IV)-deferoxamine scaffolds for potential theranostic application. Dalton Trans 55:406\u2013413. https:\/\/doi.org\/10.1039\/d5dt02352a","journal-title":"Dalton Trans"},{"key":"823_CR24","doi-asserted-by":"publisher","first-page":"6446","DOI":"10.7150\/thno.100339","volume":"14","author":"BJB Nelson","year":"2024","unstructured":"Nelson BJB, Krol V, Bansal A, Andersson JD, Wuest F, Pandey MK (2024) Aspects and prospects of preclinical theranostic radiopharmaceutical development. Theranostics 14:6446\u20136470. https:\/\/doi.org\/10.7150\/thno.100339","journal-title":"Theranostics"},{"key":"823_CR25","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.121.263301","volume":"63","author":"M Perera","year":"2022","unstructured":"Perera M, Morris MJ (2022) From concept to regulatory drug approval: lessons for theranostics. J Nucl Med 63:1793\u20131801. https:\/\/doi.org\/10.2967\/jnumed.121.263301","journal-title":"J Nucl Med"},{"key":"823_CR26","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00259-021-05541-7","volume":"49","author":"WU Kampen","year":"2022","unstructured":"Kampen WU, Boddenberg-P\u00e4tzold B, Fischer M et al (2022) The EANM guideline for radiosynoviorthesis. Eur J Nucl Med Mol Imaging 49:681\u2013708. https:\/\/doi.org\/10.1007\/s00259-021-05541-7","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"823_CR27","doi-asserted-by":"publisher","first-page":"6300","DOI":"10.1158\/1078-0432.CCR-18-0768","volume":"24","author":"B Grubmuller","year":"2018","unstructured":"Grubmuller B, Baltzer P, Hartenbach S et al (2018) PSMA ligand PET\/MRI for primary prostate cancer: staging performance and clinical impact. Clin Cancer Res 24:6300\u20136307. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0768","journal-title":"Clin Cancer Res"},{"key":"823_CR28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/jmri.28431","volume":"57","author":"V Romeo","year":"2023","unstructured":"Romeo V, Helbich TH, Pinker K (2023) Breast PET\/MRI hybrid imaging and targeted tracers. J Magn Reson Imaging 57:370\u2013386. https:\/\/doi.org\/10.1002\/jmri.28431","journal-title":"J Magn Reson Imaging"},{"key":"823_CR29","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1007\/s00259-020-05082-5","volume":"48","author":"S Rasul","year":"2021","unstructured":"Rasul S, Hartenbach M, Wollenweber T et al (2021) Prediction of response and survival after standardized treatment with 7400 MBq \u00b9\u2077\u2077Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 48:1650\u20131657. https:\/\/doi.org\/10.1007\/s00259-020-05082-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"823_CR30","doi-asserted-by":"publisher","first-page":"46H","DOI":"10.1016\/0002-9149(92)90646-g","volume":"69","author":"S Kaul","year":"1992","unstructured":"Kaul S (1992) Clinical applications of myocardial contrast echocardiography. Am J Cardiol 69:46H\u201355H. https:\/\/doi.org\/10.1016\/0002-9149(92)90646-g","journal-title":"Am J Cardiol"},{"key":"823_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404411","volume":"12","author":"V Pichler","year":"2025","unstructured":"Pichler V, Martinho RP, Temming L, Segers T, Wurm FR, Koshkina O (2025) The environmental impact of medical imaging agents and the roadmap to sustainable medical imaging. Adv Sci 12: e2404411. https:\/\/doi.org\/10.1002\/advs.202404411","journal-title":"Adv Sci"},{"key":"823_CR32","doi-asserted-by":"publisher","first-page":"4866","DOI":"10.1016\/j.bpj.2009.02.072","volume":"96","author":"N Kudo","year":"2009","unstructured":"Kudo N, Okada K, Yamamoto K (2009) Sonoporation by single-shot pulsed ultrasound with microbubbles adjacent to cells. Biophys J 96:4866\u20134876. https:\/\/doi.org\/10.1016\/j.bpj.2009.02.072","journal-title":"Biophys J"},{"key":"823_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2024.01.028","volume":"367","author":"P Nittayacharn","year":"2024","unstructured":"Nittayacharn P, Abenojar E, Cooley MB et al (2024) Efficient ultrasound-mediated drug delivery to orthotopic liver tumors\u2014Direct comparison of doxorubicin-loaded nanobubbles and microbubbles. J Control Release 367:135\u2013147. https:\/\/doi.org\/10.1016\/j.jconrel.2024.01.028","journal-title":"J Control Release"},{"key":"823_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107415","volume":"217","author":"Y Yan","year":"2026","unstructured":"Yan Y, Hwang K, Lee J et al (2026) A novel microbubble delivery platform with high payload of paclitaxel upon focused ultrasound for enhanced glioblastoma treatment. Eur J Pharm Sci 217: 107415. https:\/\/doi.org\/10.1016\/j.ejps.2025.107415","journal-title":"Eur J Pharm Sci"},{"key":"823_CR35","doi-asserted-by":"publisher","unstructured":"Rath S, Saleh AO, Ahmad O, Sayed MS, Arshad MA, Hassan Abdullah H (2026) Sonothrombolysis as an adjunct to primary PCI in STEMI: a systematic review and meta-analysis of randomized trials. J Thromb Thrombolysis. https:\/\/doi.org\/10.1007\/s11239-026-03242-2","DOI":"10.1007\/s11239-026-03242-2"},{"key":"823_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.ultrasmedbio.2023.12.005","volume":"50","author":"GE Conway","year":"2024","unstructured":"Conway GE, Paranjape AN, Chen X, Villanueva FS (2024) Development of an in vitro model to study mechanisms of ultrasound-targeted microbubble cavitation\u2013mediated blood\u2013brain barrier opening. Ultrasound Med Biol 50:425\u2013433. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2023.12.005","journal-title":"Ultrasound Med Biol"},{"key":"823_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultsonch.2023.106445","volume":"97","author":"W Zhang","year":"2023","unstructured":"Zhang W, Metzger H, Vlatakis S et al (2023) Characterising the chemical and physical properties of phase-change nanodroplets. Ultrason Sonochem 97: 106445. https:\/\/doi.org\/10.1016\/j.ultsonch.2023.106445","journal-title":"Ultrason Sonochem"},{"key":"823_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultras.2025.107933","volume":"161","author":"CR Dyall","year":"2026","unstructured":"Dyall CR, Nevozhay D, Liu A et al (2026) Optimized ultrasound imaging of phase-change nanodroplets. Ultrasonics 161: 107933. https:\/\/doi.org\/10.1016\/j.ultras.2025.107933","journal-title":"Ultrasonics"},{"key":"823_CR39","doi-asserted-by":"publisher","first-page":"16235","DOI":"10.1039\/c9nr04471j","volume":"11","author":"IC Sun","year":"2019","unstructured":"Sun IC, Emelianov S (2019) Gas-generating nanoparticles for contrast-enhanced ultrasound imaging. Nanoscale 11:16235\u201316240. https:\/\/doi.org\/10.1039\/c9nr04471j","journal-title":"Nanoscale"},{"key":"823_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.partic.2022.08.001","volume":"75","author":"X Liu","year":"2023","unstructured":"Liu X, Pan X, Wang C, Liu H (2023) Modulation of reactive oxygen species to enhance sonodynamic therapy. Particuology 75:199\u2013216. https:\/\/doi.org\/10.1016\/j.partic.2022.08.001","journal-title":"Particuology"},{"key":"823_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.radonc.2021.04.021","volume":"160","author":"C Verry","year":"2021","unstructured":"Verry C, Dufort S, Villa J et al (2021) Theranostic AGuIX nanoparticles as radiosensitizer: a phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiother Oncol 160:159\u2013165. https:\/\/doi.org\/10.1016\/j.radonc.2021.04.021","journal-title":"Radiother Oncol"},{"key":"823_CR42","doi-asserted-by":"publisher","first-page":"12021","DOI":"10.1021\/acsomega.2c00223","volume":"7","author":"W Zhou","year":"2022","unstructured":"Zhou W, Liu Z, Wang N, Chen X, Sun X, Cheng Y (2022) Hafnium-based metal-organic framework nanoparticles as a radiosensitizer to improve radiotherapy efficacy in esophageal cancer. ACS Omega 7:12021\u201312029. https:\/\/doi.org\/10.1021\/acsomega.2c00223","journal-title":"ACS Omega"},{"key":"823_CR43","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1470-2045(19)30326-2","volume":"20","author":"S Bonvalot","year":"2019","unstructured":"Bonvalot S, Rutkowski PL, Thariat J et al (2019) NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): A multicentre, phase 2\u20133, randomised, controlled trial. Lancet Oncol 20:1148\u20131159. https:\/\/doi.org\/10.1016\/S1470-2045(19)30326-2","journal-title":"Lancet Oncol"},{"key":"823_CR44","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1039\/d3sc00251a","volume":"14","author":"LL Zhou","year":"2023","unstructured":"Zhou LL, Guan Q, Zhou W, Kan JL, Dong YB (2023) An iodide-containing covalent organic framework for enhanced radiotherapy. Chem Sci 14:3642\u20133651. https:\/\/doi.org\/10.1039\/d3sc00251a","journal-title":"Chem Sci"},{"key":"823_CR45","doi-asserted-by":"publisher","first-page":"17401","DOI":"10.1021\/acsnano.1c01435","volume":"15","author":"BL Cline","year":"2021","unstructured":"Cline BL, Jiang W, Lee C et al (2021) Potassium iodide nanoparticles enhance radiotherapy against breast cancer by exploiting the sodium-iodide symporter. ACS Nano 15:17401\u201317411. https:\/\/doi.org\/10.1021\/acsnano.1c01435","journal-title":"ACS Nano"},{"key":"823_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1148\/radiology.178.1.1898538","volume":"178","author":"G Elizondo","year":"1991","unstructured":"Elizondo G, Fretz CJ, Stark DD et al (1991) Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging. Radiology 178:73\u201378. https:\/\/doi.org\/10.1148\/radiology.178.1.1898538","journal-title":"Radiology"},{"key":"823_CR47","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.drudis.2014.11.008","volume":"20","author":"JOG Karlsson","year":"2015","unstructured":"Karlsson JOG, Ignarro LJ, Lundstr\u00f6m I, Jynge P, Alm\u00e9n T (2015) Calmangafodipir [Ca\u2084Mn(DPDP)\u2085], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discov Today 20:411\u2013421. https:\/\/doi.org\/10.1016\/j.drudis.2014.11.008","journal-title":"Drug Discov Today"},{"key":"823_CR48","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3390\/pharmaceutics14112319","volume":"14","author":"I Pashkunova-Martic","year":"2022","unstructured":"Pashkunova-Martic I, Kukeva R, Stoyanova R et al (2022) Novel salinomycin-based paramagnetic complexes\u2014first evaluation of their potential theranostic properties. Pharmaceutics 14:2319. https:\/\/doi.org\/10.3390\/pharmaceutics14112319","journal-title":"Pharmaceutics"},{"key":"823_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-018-0130-1","volume":"22","author":"Y Jeong","year":"2018","unstructured":"Jeong Y, Hwang HS, Na K (2018) Theranostics and contrast agents for magnetic resonance imaging. Biomater Res 22: 20. https:\/\/doi.org\/10.1186\/s40824-018-0130-1","journal-title":"Biomater Res"},{"key":"823_CR50","doi-asserted-by":"publisher","first-page":"8706","DOI":"10.7150\/thno.57004","volume":"11","author":"B Brito","year":"2021","unstructured":"Brito B, Price TW, Gallo J, Ba\u00f1obre-L\u00f3pez M, Stasiuk GJ (2021) Smart magnetic resonance imaging-based theranostics for cancer. Theranostics 11:8706\u20138737. https:\/\/doi.org\/10.7150\/thno.57004","journal-title":"Theranostics"},{"key":"823_CR51","doi-asserted-by":"publisher","first-page":"10503","DOI":"10.2147\/IJN.S529003","volume":"20","author":"L Zhu","year":"2025","unstructured":"Zhu L, Jiang Y, Tian H et al (2025) Recent advancement in MRI-based nanotheranostic agents for tumor diagnosis and therapy integration. Int J Nanomedicine 20:10503\u201310540. https:\/\/doi.org\/10.2147\/IJN.S529003","journal-title":"Int J Nanomedicine"},{"key":"823_CR52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V (2012) PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 161:505\u2013522. https:\/\/doi.org\/10.1016\/j.jconrel.2012.01.043","journal-title":"J Control Release"},{"key":"823_CR53","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1016\/j.biomaterials.2011.05.047","volume":"32","author":"HW Yang","year":"2011","unstructured":"Yang HW, Hua MY, Liu HL et al (2011) Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials 32:6523\u20136532. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.05.047","journal-title":"Biomaterials"},{"key":"823_CR54","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.7150\/thno.27828","volume":"8","author":"S Ray","year":"2018","unstructured":"Ray S, Li Z, Hsu CH et al (2018) Dendrimer- and copolymer-based nanoparticles for magnetic resonance cancer theranostics. Theranostics 8:6322\u20136349. https:\/\/doi.org\/10.7150\/thno.27828","journal-title":"Theranostics"},{"key":"823_CR55","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.2217\/nnm.12.198","volume":"8","author":"A Khurana","year":"2013","unstructured":"Khurana A, Nejadnik H, Chapelin F et al (2013) Ferumoxytol: a new, clinically applicable label for stem-cell tracking in arthritic joints with MRI. Nanomedicine 8:1969\u20131983. https:\/\/doi.org\/10.2217\/nnm.12.198","journal-title":"Nanomedicine"},{"key":"823_CR56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cis.2011.04.003","volume":"166","author":"S Laurent","year":"2011","unstructured":"Laurent S, Dutz S, H\u00e4feli UO, Mahmoudi M (2011) Magnetic fluid hyperthermia: focus on superparamagnetic iron oxide nanoparticles. Adv Colloid Interface Sci 166:8\u201323. https:\/\/doi.org\/10.1016\/j.cis.2011.04.003","journal-title":"Adv Colloid Interface Sci"},{"key":"823_CR57","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1021\/nn900761s","volume":"3","author":"JY Park","year":"2009","unstructured":"Park JY, Baek MJ, Choi ES et al (2009) Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T1 MRI contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and in vivo T1 MR images. ACS Nano 3:3663\u20133669. https:\/\/doi.org\/10.1021\/nn900761s","journal-title":"ACS Nano"},{"key":"823_CR58","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1021\/ja057254a","volume":"128","author":"X Huang","year":"2006","unstructured":"Huang X, El-Sayed IH, Qian W, El-Sayed MA (2006) Cancer cell imaging and photothermal therapy in the near-infrared region by using gold nanorods. J Am Chem Soc 128:2115\u20132120. https:\/\/doi.org\/10.1021\/ja057254a","journal-title":"J Am Chem Soc"},{"key":"823_CR59","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/sj.clp","volume":"83","author":"L Zhang","year":"2008","unstructured":"Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC (2008) Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther 83:761. https:\/\/doi.org\/10.1038\/sj.clp","journal-title":"Clin Pharmacol Ther"},{"key":"823_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-022-00303-4","volume":"26","author":"S Yoon","year":"2022","unstructured":"Yoon S, Cheon SY, Park S et al (2022) Recent advances in optical imaging through deep tissue: Imaging probes and techniques. Biomater Res 26: 57. https:\/\/doi.org\/10.1186\/s40824-022-00303-4","journal-title":"Biomater Res"},{"key":"823_CR61","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7150\/thno.87783","volume":"14","author":"Y Fan","year":"2024","unstructured":"Fan Y, Liu S, Gao E et al (2024) The LMIT: light-mediated minimally-invasive theranostics in oncology. Theranostics 14:341\u2013362. https:\/\/doi.org\/10.7150\/thno.87783","journal-title":"Theranostics"},{"key":"823_CR62","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.2174\/156802610791384270","volume":"10","author":"S Lee","year":"2010","unstructured":"Lee S, Xie J, Chen X (2010) Activatable molecular probes for cancer imaging. Theranostics 10:1135\u20131144. https:\/\/doi.org\/10.2174\/156802610791384270","journal-title":"Theranostics"},{"key":"823_CR63","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3322\/caac.20114","volume":"61","author":"P Agostinis","year":"2011","unstructured":"Agostinis P, Berg K, Cengel KA et al (2011) Photodynamic therapy of cancer: an update. CA Cancer J Clin 61:250\u2013281. https:\/\/doi.org\/10.3322\/caac.20114","journal-title":"CA Cancer J Clin"},{"key":"823_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fphy.2015.00030","volume":"3","author":"KC Blanco","year":"2015","unstructured":"Blanco KC, Moriyama LT, Inada NM et al (2015) Fluorescence guided PDT for optimization of the outcome of skin cancer treatment. Front Phys 3: 30. https:\/\/doi.org\/10.3389\/fphy.2015.00030","journal-title":"Front Phys"},{"key":"823_CR65","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1039\/d5na00671f","volume":"8","author":"S Priya","year":"2025","unstructured":"Priya S, Sharma D, Jain KK, Chutani S, Singhvi G (2025) Targeted nanocarriers integrating photodynamic and photothermal therapy: a paradigm shift in rheumatoid arthritis treatment. Nanoscale Adv 8:725\u2013742. https:\/\/doi.org\/10.1039\/d5na00671f","journal-title":"Nanoscale Adv"},{"key":"823_CR66","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/nature06917","volume":"452","author":"R Weissleder","year":"2008","unstructured":"Weissleder R, Pittet MJ (2008) Imaging in the era of molecular oncology. Nature 452:580\u2013589. https:\/\/doi.org\/10.1038\/nature06917","journal-title":"Nature"},{"key":"823_CR67","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1021\/ar200106e","volume":"44","author":"JV Jokerst","year":"2011","unstructured":"Jokerst JV, Gambhir SS (2011) Molecular imaging with theranostic nanoparticles. Acc Chem Res 44:1050\u20131060. https:\/\/doi.org\/10.1021\/ar200106e","journal-title":"Acc Chem Res"},{"key":"823_CR68","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nm.1854","volume":"15","author":"Y Urano","year":"2009","unstructured":"Urano Y, Asanuma D, Hama Y et al (2009) Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15:104\u2013109. https:\/\/doi.org\/10.1038\/nm.1854","journal-title":"Nat Med"},{"key":"823_CR69","doi-asserted-by":"publisher","first-page":"13549","DOI":"10.1073\/pnas.2232479100","volume":"23","author":"LR Hirsch","year":"2003","unstructured":"Hirsch LR, Stafford RJ, Bankson JA et al (2003) Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci USA 23:13549\u201313554. https:\/\/doi.org\/10.1073\/pnas.2232479100","journal-title":"Proc Natl Acad Sci USA"},{"key":"823_CR70","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejrad.2013.05.028","volume":"83","author":"H Jadvar","year":"2014","unstructured":"Jadvar H, Colletti PM (2014) Competitive advantage of PET\/MRI. Eur J Radiol 83:84\u201394. https:\/\/doi.org\/10.1016\/j.ejrad.2013.05.028","journal-title":"Eur J Radiol"},{"key":"823_CR71","doi-asserted-by":"publisher","first-page":"345","DOI":"10.2967\/jnumed.111.099754","volume":"53","author":"F Kiessling","year":"2012","unstructured":"Kiessling F, Fokong S, Koczera P, Lederle W, Lammers T (2012) Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics. J Nucl Med 53:345\u2013348. https:\/\/doi.org\/10.2967\/jnumed.111.099754","journal-title":"J Nucl Med"},{"key":"823_CR72","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1021\/acs.chemrev.8b00363","volume":"119","author":"J Wahsner","year":"2019","unstructured":"Wahsner J, Gale EM, Rodr\u00edguez-Rodr\u00edguez A, Caravan P (2019) Chemistry of MRI contrast agents: current challenges and new frontiers. Chem Rev 119:957\u20131057. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00363","journal-title":"Chem Rev"},{"key":"823_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10450","volume":"8","author":"AH Liao","year":"2023","unstructured":"Liao AH, Wang CH, Wang BH et al (2023) Combined use of microbubbles of various sizes and single-transducer dual-frequency ultrasound for safe and efficient inner ear drug delivery. Bioeng Transl Med 8: e10450. https:\/\/doi.org\/10.1002\/btm2.10450","journal-title":"Bioeng Transl Med"},{"key":"823_CR74","doi-asserted-by":"publisher","first-page":"26665","DOI":"10.1039\/d2ra04467f","volume":"12","author":"U Masood","year":"2022","unstructured":"Masood U, Riaz R, Shah SU, Majeed AI, Abbas SR (2022) Contrast enhanced sonothrombolysis using streptokinase loaded phase change nano-droplets for potential treatment of deep venous thrombosis. RSC Adv 12:26665\u201326672. https:\/\/doi.org\/10.1039\/d2ra04467f","journal-title":"RSC Adv"},{"key":"823_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-07753-0","volume":"7","author":"N Kumar","year":"2017","unstructured":"Kumar N, George BPA, Abrahamse H, Parashar V, Ray SS, Ngila JC (2017) A novel approach to low-temperature synthesis of cubic HfO\u2082 nanostructures and their cytotoxicity. Sci Rep 7: 9351. https:\/\/doi.org\/10.1038\/s41598-017-07753-0","journal-title":"Sci Rep"},{"key":"823_CR76","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejca.2021.01.007","volume":"146","author":"C Hoffmann","year":"2021","unstructured":"Hoffmann C, Calugaru V, Borcoman E et al (2021) Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx. Eur J Cancer 146:135\u2013144. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.007","journal-title":"Eur J Cancer"},{"key":"823_CR77","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.3892\/ijmm.2016.2744","volume":"38","author":"YD Xiao","year":"2016","unstructured":"Xiao YD, Paudel R, Liu J, Ma C, Zhang ZS, Zhou SK (2016) MRI contrast agents: classification and application. Int J Mol Med 38:1319\u20131326. https:\/\/doi.org\/10.3892\/ijmm.2016.2744","journal-title":"Int J Mol Med"},{"key":"823_CR78","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1039\/c9sc05937g","volume":"11","author":"CJ Adams","year":"2020","unstructured":"Adams CJ, Meade TJ (2020) Gd(III)-Pt(IV) theranostic contrast agents for tandem MR imaging and chemotherapy. Chem Sci 11:2524\u20132530. https:\/\/doi.org\/10.1039\/c9sc05937g","journal-title":"Chem Sci"},{"key":"823_CR79","doi-asserted-by":"publisher","first-page":"16552","DOI":"10.1021\/acs.analchem.1c03744","volume":"93","author":"A Li","year":"2021","unstructured":"Li A, Luo X, Li L et al (2021) Activatable multiplexed \u00b9\u2079F magnetic resonance imaging visualizes reactive oxygen and nitrogen species in drug-induced acute kidney injury. Anal Chem 93:16552\u201316561. https:\/\/doi.org\/10.1021\/acs.analchem.1c03744","journal-title":"Anal Chem"}],"container-title":["European Radiology Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-026-00823-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41747-026-00823-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-026-00823-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:37:24Z","timestamp":1791448644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41747-026-00823-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["823"],"URL":"https:\/\/doi.org\/10.1186\/s41747-026-00823-x","relation":{},"ISSN":["2509-9280"],"issn-type":[{"value":"2509-9280","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]},"assertion":[{"value":"2 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests related to the content of this manuscript.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"152"}}